Pneumonia Therapeutics Market Size and Forecasts (2021 - 2031), Global and Regional Share, Trends, and Growth Opportunity Analysis

MARKET INTRODUCTION

Pneumonia is a term used to describe a disorder that affects the alveoli of the lungs. Pneumonia is caused by bacteria, fungi, or viruses, and is responsible for 5-6% of all deaths in children under the age of five. In the pediatric population of African nations, the prevalence of pneumonia is substantially high. Due to high rate of morbidity and mortality associated with pneumococcal infection and rise in the number of resistant strains, pneumonia preventive therapy has become common. The vaccines' high preventive rates, 5-year immunization plan, and increasing regulatory support for vaccination are expected to provide lucrative growth opportunities.
MARKET DYNAMIC
Factors driving the growth of the pneumonia therapeutics market are growing number of ongoing clinical trials for vaccine development and drug molecules, and surging cases of pneumonia across the globe. However, low treatment rates in developing economies is likely to hamper the growth of the market. Moreover, increasing funding opportunities in R&D for new product development is likely to create growth opportunities in the market.

MARKET SCOPE

The "Pneumonia Therapeutics Market Analysis to 2031" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of pneumonia therapeutics market with detailed market segmentation by product, indication type, and distribution channel. The pneumonia therapeutics market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in pneumonia therapeutics market and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The pneumonia therapeutics market is segmented based on product, indication type, and distribution channel. Based on product, the market is categorized as branded drugs, generic drugs, vaccines, and others. The branded drugs market is further segmented into aminopenicillins, carbapenems, quinolones, macrolides, B-lactamase inhibitors, tetracyclines, cephalosporins, glycopeptide antibiotics, and others. The generic drugs market is further segmented into quinolones, macrolides, and others. Based on indication type, the market is categorized as hospital-acquired pneumonia (HAP), community-acquired pneumonia (CAP), and ventilator-associated pneumonia (VAP). Based on distribution channel, the market is categorized as hospital pharmacies, retail pharmacies, and online pharmacies.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the pneumonia therapeutics market based on various segments. It also provides market size and forecast estimates from year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The pneumonia therapeutics market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting pneumonia therapeutics market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the pneumonia therapeutics market in these regions.

MARKET PLAYERS

The report covers key developments in the pneumonia therapeutics market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from pneumonia therapeutics market are anticipated to have lucrative growth opportunities in the future with the rising demand for pneumonia therapeutics in the global market. Below mentioned is the list of few companies engaged in the pneumonia therapeutics market.

The report also includes the profiles of key players in pneumonia therapeutics market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, products and services offered, financial information of last 3 years, key development in past five years.

•   Pfizer, Inc.
  
•   Merck & Co., Inc.
  
•   GlaxoSmithKline Plc
  
•   Bayer AG
  
•   Novartis AG
  
•   Allergan
  
•   Lupin Pharmaceuticals, Inc.
  
•   Smith & Nephew
  
•   Abbott
  
•   Cipla
  

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.

Pneumonia Therapeutics Report Scope